Pharmaceutical conglomerate Ipsen is set to be a beneficiary of Radius Health’s flotation, despite never investing money in the company, it has emerged.

According to a source within Ipsen, Ipsen did not invest any cash in Radius directly, but took an equity share worth about 1% in Radius…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?